NASDAQ:RGENRepligen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $139.51 -0.80 (-0.57 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$136.64Now: $139.51▼$140.9950-Day Range$96.50MA: $116.67▼$140.4852-Week Range$66.21Now: $139.51▼$143.93Volume307,924 shsAverage Volume512,169 shsMarket Capitalization$7.30 billionP/E Ratio310.03Dividend YieldN/ABeta1.06 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.6 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $129.17, Repligen has a potential downside of 7.4% from its current price of $139.51.Amount of Analyst CoverageRepligen has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesRepligen has received 347 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRepligen has received 322 “underperform” votes. (Add your “underperform” vote.)Community SentimentRepligen has received 51.87% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote “Outperform” if you believe RGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,842,130.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Repligen is held by insiders.Percentage Held by Institutions89.18% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 17.70% in the coming year, from $1.13 to $1.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 310.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 310.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.17.Price to Earnings Growth RatioRepligen has a PEG Ratio of 5.59. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN Previous Symbol CUSIP75991610 CIK730272 Webwww.repligen.com Phone781-250-0111Debt Debt-to-Equity Ratio0.25 Current Ratio15.56 Quick Ratio14.09Price-To-Earnings Trailing P/E Ratio310.03 Forward P/E Ratio123.46 P/E Growth5.59 Sales & Book Value Annual Sales$270.24 million Price / Sales27.00 Cash Flow$1.41 per share Price / Cash Flow98.96 Book Value$20.36 per share Price / Book6.85Profitability EPS (Most Recent Fiscal Year)$1.07 Net Income$21.41 million Net Margins8.11% Return on Equity5.55% Return on Assets4.28%Miscellaneous Employees548 Outstanding Shares52,306,000Market Cap$7.30 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:RGEN Rates by TradingView Receive RGEN News and Ratings via Email Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Repligen (NASDAQ:RGEN) Frequently Asked Questions How has Repligen's stock been impacted by COVID-19 (Coronavirus)? Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGEN stock has increased by 53.3% and is now trading at $139.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Repligen? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Repligen. When is Repligen's next earnings date? Repligen is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Repligen. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) issued its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.22 by $0.10. The biotechnology company earned $76.09 million during the quarter, compared to analyst estimates of $71.79 million. Repligen had a return on equity of 5.55% and a net margin of 8.11%. The firm's revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share. View Repligen's earnings history. What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY 2020 Pre-Market earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of 1.09-1.14 for the period, compared to the Thomson Reuters consensus estimate of $0.99. The company issued revenue guidance of $309-319 million, compared to the consensus revenue estimate of $307.92 million. What price target have analysts set for RGEN? 6 analysts have issued 12 month price targets for Repligen's stock. Their forecasts range from $110.00 to $150.00. On average, they anticipate Repligen's share price to reach $129.17 in the next year. This suggests that the stock has a possible downside of 7.4%. View analysts' price targets for Repligen. What are Wall Street analysts saying about Repligen stock? Here are some recent quotes from research analysts about Repligen stock: 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019) 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019) Has Repligen been receiving favorable news coverage? Media headlines about RGEN stock have been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutRepligen. Are investors shorting Repligen? Repligen saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,520,000 shares, a decline of 15.7% from the April 30th total of 2,990,000 shares. Based on an average trading volume of 590,000 shares, the short-interest ratio is presently 4.3 days. Currently, 5.3% of the shares of the stock are short sold. View Repligen's Current Options Chain. Who are some of Repligen's key competitors? Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Trade Desk (TTD), Veeva Systems (VEEV), Advanced Micro Devices (AMD), Netflix (NFLX), Shopify (SHOP), Square (SQ) and Micron Technology (MU). Who are Repligen's key executives? Repligen's management team includes the following people: Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)Mr. Jon K. Snodgres, CFO & Sec. (Age 53)Mr. Steve Curran, VP of Global OperationsMs. Sondra S. Newman, Sr. Director of Investor RelationsMr. Stephen Tingley, VP of Sales What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (4.17%), State Street Corp (3.04%), Conestoga Capital Advisors LLC (2.58%), Fred Alger Management LLC (1.98%), Alliancebernstein L.P. (1.88%) and Geode Capital Management LLC (1.43%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View institutional ownership trends for Repligen. Which institutional investors are selling Repligen stock? RGEN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, 1832 Asset Management L.P., Federated Hermes Inc., Lord Abbett & CO. LLC, Fred Alger Management LLC, UBS Group AG, California Public Employees Retirement System, and Principal Financial Group Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr. View insider buying and selling activity for Repligen. Which institutional investors are buying Repligen stock? RGEN stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Ardevora Asset Management LLP, Canada Pension Plan Investment Board, Franklin Resources Inc., FDx Advisors Inc., FDx Advisors Inc., Impax Asset Management Group plc, and Strs Ohio. View insider buying and selling activity for Repligen. How do I buy shares of Repligen? Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $139.51. How big of a company is Repligen? Repligen has a market capitalization of $7.30 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis. Repligen employs 548 workers across the globe. What is Repligen's official website? The official website for Repligen is www.repligen.com. How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
